MOLN Molecular Partners

Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit

Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 19, 2023 (GLOBE NEWSWIRE) -- AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that the Company will present in a fireside chat at the TD Cowen Radiopharmaceutical Innovation Summit on Tuesday, June 20, 2023 at 12:00 p.m. ET. Presenting on behalf of Molecular Partners will be Patrick Amstutz, Chief Executive Officer, and Daniel Steiner, SVP Research.  

A live webcast of the event will be available on the "News and Events" page in the "Events" section of the . A replay of the webcast will be archived on the Company's website for 1 year following their respective presentation dates.

About Molecular Partners AG  

Molecular Partners AG is a clinical-stage biotech company developing DARPin (designed ankyrin repeat protein) therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics in the areas of oncology and virology and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.  Find us on Twitter - 

For further details, please contact:

Seth Lewis, Investor Relations

Tel:

Antonio Ligi, Communications

Zurich-Schlieren, Switzerland



Tel: 1



EN
19/06/2023

Underlying

MOLNMolecular Partners

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Molecular Partners

 PRESS RELEASE
Free
MOLN Molecular Partn...

Molecular Partners and Orano Med present preclinical data on mesotheli...

Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025 MP0726, a Radio-DARPin candidate targeting mesothelin (MSLN) and intended for the treatment of ovarian cancer, is nominated for development under strategic partnership with Orano MedPromising tumor accumulation and attractive biodistribution shown in vivo, selective binding to membrane-bound MSLN with positive tumor to kidney ratio ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass. and PARIS, June 22, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 ...

June 22, 2025 1 EN
 PRESS RELEASE
Free
MOLN Molecular Partn...

Molecular Partners presents positive data from ongoing Phase 1/2a tria...

Molecular Partners presents positive data from ongoing Phase 1/2a trial of MP0533 in AML at EHA 2025 Three of eight evaluable patients with R/R AML responded after cycle 1 in ongoing cohort 8, including 1 patient with ongoing response beyond 6 monthsAcceptable safety profile across all cohorts, including in cohort 8 with steeper step-up dosingData support further dose optimization to maximize therapeutic benefit of MP0533, with dosing in cohort 9 now ongoing ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR AG ...

June 11, 2025 1 EN
 PRESS RELEASE
Free
MOLN Molecular Partn...

Molecular Partners Announces Planned Operational Efficiencies and Exte...

Molecular Partners Announces Planned Operational Efficiencies and Extension of Cash Runway Guidance confirmed for clinical milestones for MP0533 and MP0712 in H2 2025Cash reach now anticipated to extend into 2028 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announces that it has performed a strategic review of its cur...

June 10, 2025 1 EN
 PRESS RELEASE
Free
MOLN Molecular Partn...

Molecular Partners to Present at Upcoming Investor Conferences

Molecular Partners to Present at Upcoming Investor Conferences ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 19, 2025 (GLOBE NEWSWIRE) --  AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced that members of the management team will participate in two upcoming investor conferences. H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ: Fireside Chat on Tuesday May 20, 2025 beginning at 3:30pm ET TD Cowen’s 6th Annual...

May 19, 2025 1 EN
 PRESS RELEASE
Free
MOLN Molecular Partn...

Molecular Partners Reports Financial Results and Highlights from Q1 20...

Molecular Partners Reports Financial Results and Highlights from Q1 2025 Clinical programs on track, with two major milestones later this year, and cash position, CHF 131 million as of March 31, 2025, expected to provide funding well into 2027IND filing and initial clinical data on first targeted Radio-DARPin therapy program, MP0712, expected in 2025; strategic partnership with Orano Med expanded from four to ten programsData from dosing cohort 8 in Phase 1/2a trial of MP0533 demonstrate increased rates and depth of responses; study protocol amendment now approved, and dosing cohort 9 enrol...

May 15, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch